Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vildagliptin · 1 trial · 1 indication
The 24 hour WMG was measured after 2 weeks of placebo treatment, and again after 2 weeks of vildagliptin treatment. Glucose was measured over a 24 hour period by having participants wear two continuous glucose monitors (CGM), which produced an average glucose value approximately every 5 minutes. Using these values, the concentration of glucose was calculated from Area Under the Curve 0-24 hours (AUC 0-24hr), and was expressed as 24 hour WMG.
| Arm | Type | Description |
|---|---|---|
| Placebo → Vildagliptin | EXPERIMENTAL | Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily |
| Name | Type | Description |
|---|---|---|
| Vildagliptin | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of type 2 diabetes mellitus on a clinical regimen that is metformin alone, up to a maximum of 3 gram per day, on a background of lifestyle measures, and has a Hemoglobin A1C at screening of \> 7%. * If on antihyperglycemic therapy with both metformin and sul...
Vildagliptin is being studied for the treatment of Type 2 Diabetes Mellitus. It is an investigational small molecule developed by Merck & Company, Inc. (MRK) and has been evaluated in a Phase 1 clinical trial. It is not approved for any indication.
Vildagliptin targets DPP4 (dipeptidyl peptidase-4). It is a DPP4 inhibitor, meaning it works by inhibiting the DPP4 enzyme. This mechanism is being investigated for its effects in Type 2 Diabetes Mellitus.
Vildagliptin is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is responsible for the clinical development of this investigational therapy for Type 2 Diabetes Mellitus.
Vildagliptin is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently active in any trials. It is an investigational drug and has not been approved by the FDA for any indication.
Vildagliptin has been evaluated in one completed Phase 1 clinical trial: NCT01537120, titled "Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)." The trial enrolled 25 participants with Type 2 Diabetes Mellitus and was uncontrolled, non-randomized, and not double-blind.